直肠癌经肛全直肠系膜切除术(taTME):超越学习曲线后的实践
该回顾性研究分析了两家三级医院2014至2019年由已完成>50例taTME的术者实施的54例直肠癌taTME病例,发现适应证已扩展至复杂再手术、局部复发、转移性肿瘤及CRM或IAS受威胁者;短期结果良好,TME完整或近完整率达94.4%,+CRM率3.7%,中位随访28个月局部复发率3.9%。
要点
- 经验丰富术者的taTME适应证可扩展至局部复发、转移性及CRM/IAS受威胁的复杂病例。
- 54例中TME完整或近完整率94.4%,+CRM率3.7%,保肛低前切除率87%。
- 中位随访28个月局部复发率3.9%、远处复发率17.6%,无癌症相关死亡。
核心结论
- 在有经验的中心,taTME适应证已扩展至复杂再手术病例、局部复发、转移性癌症及治疗后肿瘤退缩但CRM或IAS受威胁的肿瘤。
- 对于后述病例,taTME可获得良好的短期结果并可能促进R0切除。
研究设计与样本
- 回顾性分析两家三级医院2014至2019年所有直肠癌taTME病例,术者此前已完成>50例taTME。
- 共纳入54例患者,分析人口学、围术期及短期结局。
主要发现
- 54例中男性占74.1%,BMI≥30者占27.8%;肿瘤分期I期8例、II期13例、III期29例、IV期4例。
- 复杂病例包括4例局部复发、4例既往肝切除、2例既往前列腺癌;30例肿瘤距肛缘≤6 cm。
- 51例采用双团队方式,腹腔镜辅助占83.3%、机器人辅助占16.7%,中转率9.2%。
- 87%实现保留括约肌的低前切除,8例需行括约肌间切除;吻合口手缝占57.4%,全部患者行转流。
临床怎么用
- 对于局部复发、转移性癌症或CRM/IAS受威胁但治疗后肿瘤退缩的复杂直肠癌,可考虑在有经验的中心行taTME。
- taTME可促进R0切除并实现保肛,但需注意30天并发症率及术后死亡风险。
局限性
- 回顾性研究设计,样本量54例,来自两家三级医院,结果外推需谨慎。
- 缺乏非taTME对照组,无法直接比较疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transanal total mesorectal excision (taTME) is a surgical approach for low rectal cancer with a learning curve estimated at 40-50 cases. The experience among taTME surgeons beyond their learning curve is limited. METHODS: A retrospective analysis of all taTME cases performed for rectal cancer at two tertiary care hospitals from 2014 to 2019 was conducted. Transanal surgeons had previously performed > 50 taTME cases. Demographic, perioperative, and short-term outcomes were analyzed. RESULTS: Among 54 taTME patients, 74.1% were male and 27.8% had a BMI ≥ 30. Tumors were stage I (8), II (13), III (29), and IV (4). Complex cases included 4 local recurrences, 4 prior liver resections, and 2 with prior prostate cancer. Thirty tumors were located ≤ 6 cm from the anal verge. On staging MRI, 12 had a positive predicted circumferential radial margin (+CRM), and 4 had internal anal sphincter involvement (+IAS). Forty-seven patients received neoadjuvant therapy. A 2-team approach was used in 51 patients with laparoscopic (83.3%) or robotic (16.7%) abdominal assistance with a 9.2% conversion rate. Low anterior resection with sphincter salvage was achieved in 87% with 8 patients requiring intersphincteric resection. Anastomoses were hand-sewn in 57.4% and all patients were diverted. Median LOS was 5 days with a 42.6% 30-day morbidity rate and 3 postoperative mortalities (ARDS, pulmonary embolism and pseudomembranous colitis). Complete and near complete TME grade was achieved in 94.4% with a 3.7% rate of +CRM. At a median follow-up of 28 months, local and distant recurrence rates were 3.9% and 17.6%, respectively, with no cancer-related mortality. CONCLUSION: Indications for taTME at experienced centers have expanded to include complex reoperative cases, local recurrences, metastatic cancer, and tumors with threatened CRM or IAS with evidence of post-treatment tumor regression. In the latter cases, taTME achieves good short-term outcomes and may facilitate R0 resection.
引用
- D'Andrea AP, McLemore EC, Bonaccorso A, et al. Transanal total mesorectal excision (taTME) for rectal cancer: beyond the learning curve. Surg Endosc. 2019. PMID: 31602515. doi:10.1007/s00464-019-07172-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。